Alumis Inc. (NASDAQ:ALMS) Receives Consensus Rating of “Moderate Buy” from Analysts

Alumis Inc. (NASDAQ:ALMS) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $37.6667.

ALMS has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a report on Monday, December 29th. UBS Group restated an “outperform” rating on shares of Alumis in a research note on Tuesday. Guggenheim boosted their price target on shares of Alumis from $18.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $40.00 price target (up from $20.00) on shares of Alumis in a report on Friday. Finally, Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a report on Saturday, December 6th.

Insider Activity at Alumis

In other Alumis news, Director James B. Tananbaum acquired 190,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The shares were purchased at an average price of $6.56 per share, with a total value of $1,249,680.00. Following the completion of the acquisition, the director directly owned 2,542,003 shares of the company’s stock, valued at approximately $16,675,539.68. The trade was a 8.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Srinivas Akkaraju bought 186,377 shares of Alumis stock in a transaction on Friday, December 5th. The stock was acquired at an average cost of $9.84 per share, with a total value of $1,833,949.68. Following the acquisition, the director owned 1,265,253 shares of the company’s stock, valued at $12,450,089.52. This trade represents a 17.28% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 2,788,875 shares of company stock worth $18,352,357 over the last three months. 40.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after acquiring an additional 4,926 shares during the period. Goldman Sachs Group Inc. increased its stake in Alumis by 24.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock valued at $378,000 after purchasing an additional 11,949 shares in the last quarter. Jane Street Group LLC purchased a new stake in Alumis during the first quarter worth $111,000. Rhumbline Advisers boosted its position in Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after purchasing an additional 2,949 shares in the last quarter. Finally, Kera Capital Partners Inc. purchased a new position in shares of Alumis in the second quarter valued at $32,000.

Alumis Stock Performance

Shares of ALMS opened at $19.56 on Friday. Alumis has a fifty-two week low of $2.76 and a fifty-two week high of $22.30. The firm has a 50-day simple moving average of $9.21 and a 200-day simple moving average of $5.91. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of -4.83 and a beta of -2.09.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to the consensus estimate of $3.14 million. Equities research analysts forecast that Alumis will post -8.51 EPS for the current year.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.